VCM
LAB icon

Voleon Capital Management’s Standard BioTools LAB Stock Holding History

Voleon Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,350
Closed -$13.2K – 856
2025
Q4 		$13.2K Buy
+10,350
New +$13.9K ﹤0.01% 770

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Voleon Capital Management's LAB Position: Q1 2026 in Review

Voleon Capital Management sold out of Standard BioTools (LAB) in Q1 2026, closing a stake of 10,350 shares — an estimated $13.2K sold.

Voleon Capital Management first reported a position in LAB in Q4 2025 and held it in 1 quarter. The position peaked at $13.2K in Q4 2025. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • Voleon Capital Management reported no remaining Standard BioTools position as of Q1 2026 after selling out during the quarter.
  • Voleon Capital Management sold 10,350 Standard BioTools shares in Q1 2026, an estimated $13.2K.
  • Voleon Capital Management first reported a position in Standard BioTools in Q4 2025 and held it in 1 quarter.
  • Voleon Capital Management's Standard BioTools position peaked at $13.2K in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Voleon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.